I know insurance companies can reach very high values, so naturally ALL is interesting to be, as a company that is yet to make a breakthrough. As opposed to that thought I see more and more analysts changing their minds regarding its buy status.
So, what’s the deal here? Are they seeing something new that can negatively impact growth or has ALL reached its peak, and is realistically unable to grow anymore?
There are no replies in this thread yet. Be the first to post a reply below: